Showing results (1721-1730 of 1,800) with videos related to
Sort By:
Pageof 180
Lupus|February 14, 2009
European consensus statement on the terminology used in the management of lupus glomerulonephritisC Gordon, D Jayne, C Pusey, et al.American Journal of Respiratory and Critical Care Medicine|July 19, 2008
Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsisMark M Wurfel, Anthony C Gordon, Tarah D Holden, et al.Journal of Viral Hepatitis|May 18, 2026
Impact of Fatigue on Patient-Reported Outcomes and Work Productivity in Chronic Hepatitis B and C: Insights From a Multinational Registry StudyYusuf Yilmaz, Ming-Lung Yu, Khalid Alswat, et al.The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.The New England Journal of Medicine|April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisKris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.Journal of Hepatology|July 28, 2014
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infectionAndrew J Muir, Sanjeev Arora, Gregory Everson, et al.Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.Lupus|August 31, 2007
Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohortM B Urowitz, D Gladman, D Ibañez, et al.Health Technology Assessment (Winchester, England)|July 1, 2026
Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluationTimothy S Walsh, Richard A Parker, Leanne M Aitken, et al.The Lancet. Gastroenterology & Hepatology|October 31, 2025
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trialMichael Trauner, Cynthia Levy, Atsushi Tanaka, et al.Pageof 180